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desquamation and skin high dose area for breast
cancer patients receiving adjuvant radiotherapy
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Background: To evaluate whether the location of moist desquamation matches high dose area for breast cancer
patients receiving adjuvant radiotherapy (RT) after breast conservative surgery.
Methods: One hundred and nine breast cancer patients were enrolled to this study. Their highest skin dose area
(the hot spot) was estimated from the treatment planning. We divided the irradiated field into breast; sternal/
parasternal; axillary; and inframammary fold areas. The location for moist desquamation was recorded to see if it
matches the hot spot. We also analyzed other possible risk factors which may be related to the moist desquamation.
Results: Forty-eight patients with 65 locations developed moist desquamation during the RT course. Patients with
larger breast sizes and easy to sweat are two independent risk factors for moist desquamation. The distribution of
moist desquamation occurred most in the axillary area. All nine patients with the hot spots located at the axillary area
developed moist desquamation at the axillary area, and six out of seven patients with the hot spots located at the
inframammary fold developed moist desquamation there. The majority of patients with moist desquamation over the
breast or sternal/parasternal areas had the hot spots located at these areas.
Conclusions: For a patient with moist desquamation, if a hot spot is located at the axillary or inframammary fold areas,
it is very likely to have moist desquamation occur there. On the other hand, if moist desquamation occurs over the
breast or sternal/parasternal areas, we can highly expect these two areas are also the hot spot locations.
Keywords: Breast cancer, Radiotherapy, Radiation dermatitis, High dose areaBackground
Breast cancer is the most common type of cancer diag-
nosed among women in the United States, excluding skin
cancer [1]. According to statistics of the Department of
Health, Executive Yuan, R.O.C., it is also the most com-
mon malignancy among women in Taiwan since 1996,
and its incidence rate has increased by 22.2% from 2001
to 2005 [2]. The age-adjusted incidence rate has reached
62.38 new cases per 100,000 in 2008 [2]. Nowadays,
Breast-conserving surgery (BCS), followed by radiotherapy
(RT), has become accepted as an appropriate treatment* Correspondence: limin.sun@yahoo.com
1Department of Radiation Oncology, Zuoying Branch of Kaohsiung Armed
Forces General Hospital, 553 Junxiao Rd, Zuoying District, Kaohsiung, Taiwan
Full list of author information is available at the end of the article
© 2013 Sun et al.; licensee BioMed Central Ltd
Commons Attribution License (http://creativec
reproduction in any medium, provided the orfor women with early breast cancer [3]. The modern RT
technique can effectively reduce the dose to the under-
lying lung and heart, and the related-sequelae in these
organs can be minimized [4,5]. The skin, however, is close
to the target volume and inevitably receives a high radi-
ation dose.
Skin is relatively radiosensitive and tends to have
different degrees of damage after certain doses of radi-
ation [6]. Therefore; we can expect the appearance of
radiation dermatitis in the RT field. Moist desquamation
is common and will cause the discomfort of patients or
the interruption of treatment [7,8]. Grade II acute radi-
ation dermatitis means moderate to brisk erythema,
patchy moist desquamation (mostly confined to skin folds
and creases), and moderate edema. Grade III means moist. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 The 4 parts of irradiated area: A: main breast area;
B: sternal/parasternal area; C: axillary area; D: inframammary area.
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ing induced by minor trauma or abrasion [9]. The current
study analyzed the possible risk factors related to the oc-
currence of moist desquamation for breast cancer patients
receiving RT after BCS. The skin irradiated dose can be
reflected on the isodose curve distribution of RT treat-
ment planning, and we were interested in investigating
whether the highest skin dose area (the hot spot) can pre-
dict the location of moist desquamation appearance.
Therefore we focused on the evaluation of compatibility
of the hot spot and location of the moist desquamation.
Methods
Patients
Between June 2010 and November 2011, 109 consecu-
tive female patients with breast cancer after BCS were
referred to our department for adjuvant RT and enrolled
into this prospective study. The eligibility criteria were
that patients with pathologically proven breast carcinoma,
curative intent for RT (no stage IV disease), not recur-
rence, and ability to raise their arms steadily with a cast
holding during daily RT. There was no age limitation.
All patients’ demographic characteristics as well as other
important data were recorded. They include the patient’s
age, body mass index (BMI, calculated from the body
weight and height), breast size [volume measured by the
computed tomography (CT)], lesion side, pathological
stage defined by the seventh edition of the AJCC Cancer
Staging Manual [10], either subjective (self-reported by
patient) or objective (observed by staff ) judgment of easy
to sweat or neither, skin color (light or dark), treatment
season (at least half of treatment times were in May
through September or not), adjuvant chemotherapy and
hormone therapy.
Immobilization and treatment planning
A customized chest mold was cast for each patient for
immobilization and reproducibility during computed tom-
ography (CT) simulation and each treatment process. The
material used for the cast was the Aquaplast Thermoplas-
tic which can be easily molded and conformed to the
curvature of skin [11]. Patients received CT simulation by
the Philips ACQSim CT simulator with the cast. The radi-
ation oncologist then contoured the target on the planned
CT sections according to the guidelines of International
Commission of Radiation Units and Measurements Re-
ports 50 and 62 [12,13]. The breast margins shown on
each slice of CT images were also delineated to measure
breast volume. The radiation physicist did the planning in
the ADAC Pinnacle Treatment Planning System there-
after. The clinical target volume (CTV) included the ipsi-
lateral breast and possible axillary LNs. The RT for
internal mammary chain LNs and/or ipsilateral supra-
clavicular LNs were reserved to cases with higher risk oftumor recurrence in those areas. The planning target
volume (PTV) was CTV with extension of 0.5 to 1 cm
margins.
We used bilateral opposed tangential fields on mega-
voltage linear accelerators with three-dimensional con-
formal radiotherapy (3-D CRT) technique to cover the
breast, axillary LNs (except for stage 0 cases) and pos-
sible ipsilateral internal mammary LNs. One AP field
with a tilt of 10 to 15 degree to spare more larynx and
upper esophagus was used to cover SCF when the ipsi-
lateral supraclavicular LNs was the target. Treatment
plans were designed to deliver the prescribed dose to the
target volumes with consideration of normal tissue con-
straints. The prescribed dose for the PTV was 50.4 Gy
in 28 fractions with 6 MV x-ray, and for selected cases
with high risk factors [14], we added the surgical scar
boost for additional 10.8 Gy in 6 fractions via electron
beam. We observed the isodose distribution for each
patient and recorded the maximum point dose location
shown on the isodose distribution as the hot spot for the
overlying skin.
Treatment process
After 2 weeks of treatment, the corresponding physician
and therapist started paying attention to observe if any
moist desquamation occurs over patient’s skin, and they
documented the location and RT dose when it occurred.
Because not all patients received the electron boost for
the surgical scar, we only recorded the skin reaction dur-
ing the photon beam therapy (dose up to 50.4 Gy). We
observed the acute skin reaction every treatment day
between 3 and 6 weeks counted from the start of treat-
ment. It’s inconvenient for us to objectively document
the skin reaction after completion of RT, so we did not
record the skin reaction thereafter. In order to conveni-
ently document the hot spot area and the location of
Table 1 Univariate analysis for the relationship between
the patient’s characteristics and moist desquamation
Parameters Case
number
Moist desquamation P value
Yes No Percentage (%)
Age 0.523
< 55 65 27 38 41.5
≧55 44 21 23 47.7
BMI 0.181
< 25 51 19 32 37.3
≧25 58 29 29 50.0
Breast volume (cc) 0.004*
< 350 51 15 36 29.4
≧350 58 33 25 56.9
Side 0.492
Right 55 26 29 47.3
Left 54 22 32 40.7
Stage 0.469
0–I 61 25 36 41.0
II–III 48 23 25 47.9
Easy to sweat 0.001*
Yes 57 34 23 59.7
No 52 14 38 26.9
Skin color 0.243
Light 50 19 31 38.0
Dark 59 29 30 49.2
Summer 0.342
Yes 58 28 30 48.3
No 51 20 31 39.2
Chemotherapy 0.370
Yes 47 23 24 49.0
No 62 25 37 40.3
Hormone therapy 0.263
Yes 57 28 29 49.1
No 52 20 32 38.5
Abbreviations: BMI = Body mass index.
*Statistically significant.
Table 2 Multivariate analysis for the relationship













Abbreviations: BMI = Body mass index.
*Statistically significant.
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4 parts (Figure 1). There are: (A) main breast area,
(B) sternal/ parasternal area, (C) axillary area, and (D) infra-
mammary fold.Statistics
The chi-square test and logistic regression model were
conducted for the univariate and multivariate analyses of
the potential risk factors and moist desquamation, respect-
ively. A p-value of less than 0.05 from a two-tailed test is
considered statistically significant. All the biostatistics wereperformed by the software of Statistics with Stata (8th
Edition, Brooks/Cole Inc., Belmont, CA).
Results
Patient’s age ranged from 29 to 81 years old and median
age was 51 years of age, and the majority was younger
than 55 years of age. Breast size (represented by the
volume which was measured from the CT planning sys-
tem) ranged from 277 to 668 cc and median volume was
358 cc. The pathologic stage distribution is as below:
stage 0: 22; stage I: 39; stage IIA: 16; stage IIB: 19; stage
IIIA: 8; stage IIIB: 0; stage IIIC: 5. There were a total of
48 patients who developed moist desquamation at the
dose ranged from 32.4 Gy to 50.4 Gy with the median
dose of 45.0 Gy. Table 1 showed the results of univariate
analysis for the relationship between the patient’s demo-
graphic and moist desquamation. Breast size and easy to
sweat are the two factors with statistical significance.
Patients with breast volume 350 cc or more or easy to
sweat were prone to have moist desquamation. Larger
BMI and treatment course in summer are supposed to
have more occurrence of moist desquamation, and our
data also showed this trend. However, the statistical
analysis did not reach the significant level. Other factors
did not show significant impact to predict moist des-
quamation, either. Further multivariate analysis did not
change the results and demonstrated that the two
predictors of moist desquamation are still patients with
larger breast (p = 0.012) and easy to sweat (p = 0.007)
(Table 2).
Table 3 illustrated the distribution of the hot spot loca-
tions and its relationship to area of moist desquamation.
Each patient had one hot spot location of skin dose. The
breast area is the most common location for the hot
spot, followed by the axillary area, inframammary fold,
and sterna/parasternal area. All nine patients with the
Table 3 The distribution of the hot spot locations and its relationship to areas of moist desquamation
Moist desquamation occurred at the same area of the hot spot
The hot spot location # (total 48) Yes (%) No (%)
Axillary 9 9 (100) 0 (0)
Breast 27 11 (40.7) 16 (59.3)
Inframammary fold 7 6 (85.7) 1 (14.3)
Sternal/parasternal area 5 3 (60.0) 2 (40.0)
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desquamation at axillary area, and six out of seven
patients with skin the hot spot located at inframammary
fold developed moist desquamation exactly at inframa-
mmary fold. On the other hand, the use the hot spot to
predict the moist desquamation location is not so
expected for breast and sternal /parasternal areas.
A total of 65 locations of moist desquamation were
observed in 48 patients. The distribution of the moist
desquamation occurrence area and its relationship to the
hot spot locations were shown in Table 4. The Axillary
area is the most common site for the moist desquam-
ation appearance, followed by the breast, inframammary
fold, and sterna/parasternal area. The majority of pa-
tients with moist desquamation over the breast or ster-
nal/parasternal areas had the hot spot located at these
two areas. On the other hand, the occurrence of moist
desquamation at the axillary area and inframammary
fold are not so correlated with the hot spot location.
We also assessed the quality of treatment planning by
several parameters: V95%, V105% and V110%. V95% is
defined as the absolute volume (in cc) of PTV receiving
95% of the prescribed dose. V105% and V110% represent
the absolute volume of PTV receiving 105% and 110% of
the prescribed dose, respectively. Our data showed that
the V95% ranged from 396 to 803 cc with a mean of
606 cc, the V105% ranged from 154 to 312 cc with a
mean of 227 cc, and the V110% ranged from 67 to
148 cc with a mean of 103 cc.Discussion
This study found that those patients with larger breast
size or easy to sweat are prone to get moist desquam-
ation when they receive adjuvant RT after BCS for their
breast cancer. The moist desquamation tends to occur atTable 4 The distribution of moist desquamation occurrence a




Sternal/parasternal area 4the axillary area and inframammary fold, especially when
a hot spot of skin dose is also located at these areas.
The results from this study show the median age
for our patients was 51 years. It is younger than the
population-based data in the US which showed that the
median age at diagnosis was 61 years of age from 2003
to 2007 [15]. In fact; breast cancer in Taiwan is charac-
terized by a striking recent increase of incidence and a
relatively young median age (45-49 years) at diagnosis.
The westernization of lifestyle that is increasingly affect-
ing younger generations of the Taiwanese may play an
important role on this change [16].
The incidence of severe reaction is dependent on the
total radiation dose, the dose per fraction, the overall
treatment time, beam type and energy, and the surface
area of the skin that is exposed to radiation [17]. Our data
revealed that 48 out of 109 patients (44.0%) developed
moist desquamation. This high rate is not unexpected and
is compatible with prior studies [7,18]. Although appropri-
ate management of moist desquamation will not leave
obvious sequelae, the acute morbidity definitely impact a
patient’s quality of life. Several ways to reduce skin toxic-
ities either by using skin sparing techniques [19,20], or
local applying of prophylactic medication are under inves-
tigation [21,22].
Our data found patients with breast volume 350-cc or
larger had a significant higher risk to develop moist
desquamation. It is compatible with earlier studies which
showed larger breast size and brassiere size which has
been linked to the risk of acute skin reactions [23-25],
and this may relate to the overall treatment port size
required. In addition, larger breasts which tend to fold
over onto the chest are more predisposed to have
severer skin reaction. BMI are supposed to be correlated
to breast size, and our data also support it (p value < 0.001
by chi-square test, data not shown). However, BMI is notreas and its relationship to the hot spot locations
The hot spot located at that area
Yes (%) No (%)
9 (25.7) 26 (74.3)
11 (78.6) 3 (21.4)
6 (50.0) 6 (50.0)
3 (75.0) 1 (25.0)
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other predictive factor for moist desquamation is easy to
sweat. It is plausible because sweating usually aggravates
symptoms of skin reaction. We use both subjective and
objective ways to determine easy to sweat and get more
reliable results. Patients with easy to sweat may receive
endocrine treatment more frequently. We did an analysis
to clarify this concern, and found that there is no signifi-
cant association between hormone use and easy to sweat
in our patients (p value = 0.107 by chi-square test, data
not shown). We assumed treatment time in summer may
induce more sweating. In Taiwan, a hot and humid season
normally lasts from May to September and we chose this
period to categorize our patients into two groups for
analysis. The results showed that patients received RT
during this time frame had a higher incidence of moist
desquamation, but the difference did not reach the statis-
tical significance.
The most common location of moist desquamation for
our patients is the axillary area. It is not difficult to
understand because it is full of sweat glands and skin
creases. Only 12 patients developed moist desquamation
over the inframammary fold, and it is different from the
study of Back et al. who found that the inframammary
fold is the most common site for moist desquamation
[25]. The possible reason is that Chinese women usually
have smaller breast size than Caucasian women, and the
inframammary fold is not so prominent for our patients.
Our results found a high correlation between the risk to
develop moist desquamation and the hot spot if the hot
spot is located over the axillary or inframammary fold.
On the other hand, when moist desquamation occurs at
breast and sternal/parasternal area, the majority of them
had the hot spot located at these two areas.
This study still has some limitations which need to be
addressed. First, we did not use a more scientific method
to determine easy to sweat. Indeed, it is difficult to esti-
mate it. We tried to use both self-report (subjective) and
clinical observation (objective) ways to eliminate the
bias. Second, it is not clear to classify the exact location
when the moist desquamation is located over the margin
of two areas junction. In this instance, we counted both
areas with moist desquamation. Finally, some readers
may worry that the contouring of target and breast, and
observation of the skin reaction were done by different
faculties, and it may raise the interobserver variability.
To resolve this concern, the contouring was done by
one physician and the skin reaction was supervised by
the same physician.Conclusion
Our study discovered that the risk for adjuvant RT
induced moist desquamation is significantly higher forpatients with larger breasts or easy to sweat. The hot
spots of skin dose are suggested not to be located at the
axillary area and inframammary fold to reduce the inci-
dence of moist desquamation over these two areas.
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